JP7442823B2 - 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 - Google Patents

治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 Download PDF

Info

Publication number
JP7442823B2
JP7442823B2 JP2020554523A JP2020554523A JP7442823B2 JP 7442823 B2 JP7442823 B2 JP 7442823B2 JP 2020554523 A JP2020554523 A JP 2020554523A JP 2020554523 A JP2020554523 A JP 2020554523A JP 7442823 B2 JP7442823 B2 JP 7442823B2
Authority
JP
Japan
Prior art keywords
glp
pharmaceutical composition
peptide
sodium
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520391A (ja
JP2021520391A5 (https=
Inventor
マルティン・ヴェルレ
フロリアン・フェーガー
Original Assignee
シプルメット・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シプルメット・ゲーエムベーハー filed Critical シプルメット・ゲーエムベーハー
Publication of JP2021520391A publication Critical patent/JP2021520391A/ja
Publication of JP2021520391A5 publication Critical patent/JP2021520391A5/ja
Priority to JP2024020483A priority Critical patent/JP7744049B2/ja
Application granted granted Critical
Publication of JP7442823B2 publication Critical patent/JP7442823B2/ja
Priority to JP2025146248A priority patent/JP2025179167A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020554523A 2018-04-06 2019-04-08 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 Active JP7442823B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024020483A JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18166177.8 2018-04-06
EP18166177 2018-04-06
EP18211296.1 2018-12-10
EP18211296 2018-12-10
PCT/EP2019/058828 WO2019193204A1 (en) 2018-04-06 2019-04-08 Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020483A Division JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Publications (3)

Publication Number Publication Date
JP2021520391A JP2021520391A (ja) 2021-08-19
JP2021520391A5 JP2021520391A5 (https=) 2021-09-30
JP7442823B2 true JP7442823B2 (ja) 2024-03-05

Family

ID=66182513

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554523A Active JP7442823B2 (ja) 2018-04-06 2019-04-08 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2024020483A Active JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A Pending JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024020483A Active JP7744049B2 (ja) 2018-04-06 2024-02-14 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
JP2025146248A Pending JP2025179167A (ja) 2018-04-06 2025-09-03 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物

Country Status (4)

Country Link
US (1) US20210087250A1 (https=)
EP (1) EP3773475A1 (https=)
JP (3) JP7442823B2 (https=)
WO (1) WO2019193204A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2021142737A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Compositions and methods for treating non-alcoholic steatohepatitis (nash)
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
CA3221555A1 (en) * 2021-06-23 2022-12-29 Kimberly LONG A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
KR20230000682A (ko) * 2021-06-25 2023-01-03 한미약품 주식회사 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
EP4180060A1 (en) * 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118234742A (zh) * 2021-12-01 2024-06-21 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
CN114544812B (zh) * 2022-02-18 2023-06-30 复旦大学附属中山医院 一种代谢组合式标志物在诊断哮喘中的应用
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances
CN120129529A (zh) * 2022-04-29 2025-06-10 鹏跃医药科技有限公司 用于鼻內給药的索马鲁肽及其盐的药物組合物
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用
CN115590826B (zh) * 2022-10-21 2023-12-19 北京安必奇生物科技有限公司 一种活性蛋白黏膜给药制剂及其制备方法和应用
CN115656391B (zh) * 2022-12-12 2023-04-07 哈尔滨吉象隆生物技术有限公司 一种特立帕肽含有的杂质的检测方法
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
CN116407641A (zh) * 2023-01-12 2023-07-11 深圳奥礼生物科技有限公司 多肽稳定剂和药物组合物
TW202444407A (zh) * 2023-03-23 2024-11-16 奧孟亞股份有限公司 一種高生物利用度之口服glp促效劑藥物組合物
TW202440149A (zh) * 2023-03-23 2024-10-16 奧孟亞股份有限公司 口服glp促效劑之藥物組合物
WO2025014889A2 (en) * 2023-07-07 2025-01-16 Procompounding, Llc Semaglutide formulations
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents
US20250221990A1 (en) * 2023-08-21 2025-07-10 Cmpd Licensing, Llc Topical administration to the oral cavity
US12589135B2 (en) * 2023-08-21 2026-03-31 Cmpd Licensing, Llc Topical administration of GLP-1 receptor agonists
CN119454605B (zh) * 2023-11-30 2025-12-19 深圳奥礼生物科技有限公司 一种实现多肽口服吸收的组合物
WO2025113170A1 (zh) * 2023-12-01 2025-06-05 中山万汉制药有限公司 含有glp-1受体激动剂的经鼻给药的组合物及其制备方法与用途
WO2025166413A1 (en) * 2024-02-05 2025-08-14 Ix Biopharma Limited Compositions and methods for delivering glp-1 agonists (metabolix)
WO2025251740A1 (en) * 2024-06-03 2025-12-11 Shenzhen Oralead Pharma Co., LTD. Oral polypeptide composition
CN119454909B (zh) * 2025-01-13 2025-04-08 上海世领制药有限公司 经鼻粘膜给药的胰高血糖素样肽-1受体激动剂的制剂组合物、制备方法、用途及鼻施用器

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
JP2005027651A (ja) 2002-11-29 2005-02-03 Freunt Ind Co Ltd 水性セラック皮膜剤とその製造方法及び該皮膜剤を用いたコーティング食品とその製造方法並びにコーティング医薬品とその製造方法
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017183559A1 (ja) 2016-04-19 2017-10-26 学校法人神戸学院 薬物の経粘膜吸収促進剤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
JPS57144214A (en) * 1981-03-03 1982-09-06 Kyoto Yakuhin Kogyo Kk Pharmaceutical preparation for rectum medication
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US20030017195A1 (en) 2001-07-20 2003-01-23 Samir Mitragotri Method for oral drug delivery
BR122019021416A2 (https=) 2003-09-19 2019-12-21
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
JP6016234B2 (ja) 2009-09-30 2016-10-26 ティオマトリックス・フォルシュンクス・ウント・べラートゥンクス・ゲーエムベーハー ビタミンｂ部分構造を持つ粘膜付着性ポリマー
CN102970864A (zh) 2010-04-21 2013-03-13 那挪玛加医药有限公司 纳米颗粒药物组合物
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
CN102120781B (zh) * 2011-03-16 2013-07-17 中国药科大学 一种新型胰岛素口服纳米粒的制备及应用
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
JP2005027651A (ja) 2002-11-29 2005-02-03 Freunt Ind Co Ltd 水性セラック皮膜剤とその製造方法及び該皮膜剤を用いたコーティング食品とその製造方法並びにコーティング医薬品とその製造方法
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017183559A1 (ja) 2016-04-19 2017-10-26 学校法人神戸学院 薬物の経粘膜吸収促進剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
薬剤学，2014年，Vol. 74, No. 1，p.19-26

Also Published As

Publication number Publication date
JP2021520391A (ja) 2021-08-19
WO2019193204A1 (en) 2019-10-10
US20210087250A1 (en) 2021-03-25
EP3773475A1 (en) 2021-02-17
JP2025179167A (ja) 2025-12-09
JP7744049B2 (ja) 2025-09-25
JP2024054333A (ja) 2024-04-16

Similar Documents

Publication Publication Date Title
JP7744049B2 (ja) 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
US20260027062A1 (en) Improved oral pharmaceutical formulations of therapeutic peptides and proteins
US10905744B2 (en) Pharmaceutical formulations for the oral delivery of peptide drugs
CN107693791B (zh) 包含稳定抗体的组合物
AU2009210570B2 (en) Ester-based insulin prodrugs
EP3077008B1 (en) Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP4200319B1 (en) Annexin a1 n-terminal peptide formulations and methods
KR20170061140A (ko) 펩티드 또는 단백질 약물의 경구 전달을 위한 약제학적 제형
EP3246017B1 (en) Stable liquid formulation of amg 416 hcl (etelcalcetide)
KR20110110174A (ko) 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
EP3509573B1 (en) Pharmaceutical compositions for delivery of peptide
WO2018065634A1 (en) Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EP4262745B1 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20240299552A1 (en) Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
JP2023533797A (ja) 脂質複合体を含む経口医薬組成物
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
CN114206370A (zh) 改善下尿路症状的方法
HK1246697B (en) Stable liquid formulation of amg 416 hcl (etelcalcetide)
NZ621790B2 (en) Cardiovascular therapeutics
HK1183824A (en) Amide based glucagon superfamily peptide prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7442823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150